Sandwich High Sensitivity ELISA kit for Quantitative Detection of Human PCSK9
PCSK9 protein plays a major regulatory role in cholesterol homeostasis, mainly by reducing LDL-Receptor levels on the plasma membrane. Reduced LDLR levels result in decreased metabolism of LDL-particles, which could lead to hypercholesterolemia.
This activity made PCSK9 a novel target in cholesterol lowering therapy. The PCSK9 inhibitors (PSK9i) are a newer class of injectable drugs that have been shown to dramatically lower LDL cholesterol levels, by up to 60% when combined with a statin. PCSK9 inhibitors are monoclonal antibodies (MAbs), a type of biologic drug.
PCSK9 has a key impact not only on circulating LDL-Cholesterol level but also on cardiovascular risk and atherosclerotic process. The determination of PCSK9 levels is obviously of great diagnostic as well as treatment monitoring importance.
Please click the link to find out more about the PCSK9 ELISA.